BMS-754807 / BMS - LARVOL DELTA

Identification and validation of prognostic genes associated with mitochondrial nuclear genes in gastric cancer. (PubMed, Clin Exp Med) - "BMS-754807, Gefitinib, JQ1, Lapatinib, and Sapitinib exhibited significant differences in sensitivity between the high-risk group and the low-risk group. The results of molecular docking showed TP8A2 has stable binding ability with cytosine, COX15 with indomethacin, and TARS2 with bisacodyl. RT-qPCR revealed downregulation of ATP8A2 and upregulation of COX15 and TARS2 in GC samples. MNGs, including ATP8A2, COX15, and TARS2, demonstrated significant associations with immune infiltration, CNV, and prognostic outcomes of GC."

Biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor

A prognostic model for multiple myeloma based on lipid metabolism related genes. (PubMed, Zhong Nan Da Xue Xue Bao Yi Xue Ban) - "LRGs serve as promising biomarkers for prognosis prediction and risk stratification in MM. The overexpression of chromosomal instability-related and high-risk genetic event-associated genes in high-risk patients may explain their poorer outcomes. Given the observed resistance to bortezomib and lenalidomide in high-risk patients, combination therapies involving BMS-754807 or I-BET-762 may represent effective alternatives."

Journal • Hematological Disorders • Hematological Malignancies • Metabolic Disorders • Multiple Myeloma • Oncology • B2M • FGFR3

Migrasome-Related Prognostic Genes in Gastric Cancer: A Transcriptomic and Immunotherapeutic Analysis. (PubMed, Onco Targets Ther) - "Immune profiling showed distinct microenvironment features in high-risk groups, along with differential sensitivity to specific chemotherapeutic agents (eg, BMS-754807)...The established risk model provides novel molecular markers and potential therapeutic targets for personalized GC treatment. These findings offer critical insights for understanding GC pathogenesis and developing innovative treatment strategies."

IO biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor • TGFB1 • TGFB2 • WNT11

Comprehensive analysis of prognosis and drug sensitivity of programmed cell death pattern-related genes in gastric cancer patients. (PubMed, Sci Rep) - "Furthermore, the CDI risk score exhibited positive correlations with most drugs (except for BMS.754807). Additionally, the expression of immune checkpoint genes PDCD1, CD274, and IDO1 was notably upregulated in the low-risk CDI group. Our developed CDI model, based on 17 PCD-associated prognostic genes, can be employed for risk assessment and prognosis prediction in patients with GC."

Biomarker • IO biomarker • Journal • Gastric Cancer • Oncology • Solid Tumor • IDO1 • IL17A • PD-1 • PD-L1

Integrative Pharmacogenomics in RCC Tumoroids Uncovers Biomarker-Driven Combination Therapies (EACR 2025) - "Scaffold-free tumoroids faithfully recapitulate interpatient heterogeneity in RCC, serving as robust platforms for drug discovery. Our pharmacogenomic framework identifies actionable therapeutic vulnerabilities and predictive biomarkers, providing a rationale for personalized combination therapies."

Biomarker • Combination therapy • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IR

Machine Learning and Weighted Gene Coexpression Network-Based Identification of Biomarkers Predicting Immune Profiling and Drug Resistance in Lung Adenocarcinoma. (PubMed, Int J Genomics) - "The drug sensitivity study showed that patients in the high-risk group had higher IC50 values for BMS-754807_2171 and Doramapimod_10424. Finally, in vitro experiments demonstrated that knocking down ANLN noticeably inhibited the viability, migration, and invasion of A549 cells. This study may provide a theoretical reference for future exploration of potential diagnostic and prognostic biomarkers for LUAD."

Biomarker • IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ANLN • NMUR1

Construction of CD8+ T Cell-Associated Risk Model in Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA-Seq Data (APASL 2025) - "BMS-754807, Gemcitabine, et al exhibited sensitive to patients in low-risk group, AZD6482 and SB505124 may serve as novel potential targeted drugs for patients in high-risk group. A CD8+ T cell-associated risk scoring model consisting of KLRB1, RGS2 and TNFRSF1B has been developed to predict prognosis and provide potential drugs for HCC treatment. Table and Figure:Figure 1."

IO biomarker • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • CD8 • KLRB1 • RGS2 • TNFRSF1B

Prognostic value of disulfidptosis-associated genes in gastric cancer: a comprehensive analysis. (PubMed, Front Oncol) - "Potentially effective drugs, including BMS-754807, dabrafenib, and JQ1, were identified. This study developed a novel prognostic model for gastric cancer using DRLs, identifying two key signaling axes related to prognosis. JQ1 may be an effective treatment, and FRMD6-AS could be a promising therapeutic target."

Journal • Tumor mutational burden • Cardiovascular • Gastric Cancer • Oncology • Solid Tumor • FRMD6 • TLN1 • TMB

Construction of a lung adenocarcinoma prognostic model based on KEAP1/NRF2/HO‑1 mutation‑mediated upregulated genes and bioinformatic analysis. (PubMed, Oncol Lett) - "Drug sensitivity analysis revealed that the high-risk group exhibited increased sensitivity towards vinblastine, docetaxel and cisplatin, whereas the low-risk group showed increased sensitivity to BMS_754807, SB505124_1194 and JQ1_2172. In conclusion, a KNHMUGs-based gene signature was constructed in the present study, which holds promise as a biomarker for evaluating patient prognosis and guiding treatment by effectively assessing immunotherapy response and chemotherapy sensitivity in patients with LUAD."

IO biomarker • Journal • Hepatology • Infectious Disease • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BTLA • CD4 • CD8 • CTLA4 • HAVCR2 • HMOX1 • KEAP1 • KYNU • TIGIT

NOS2 as a prognostic biomarker for early-onset colorectal cancer based on public data and clinical validation analysis. (PubMed, Sci Rep) - "Sensitivity analysis of chemotherapy drugs showed that NOS2 was significantly correlated with several chemotherapy drugs, such as MG.132_1862, BMS.754807_2171, and GEN.317_1926. Clinical validation analysis showed that the expression of NOS2 and its related genes CXCL1 and CXCL2 were significantly decreased in EOCRC patients. The results suggested that NOS2 can be used as a potential biomarker for EOCRC, which can be used for prognosis and guidance of immunotherapy and chemotherapy."

Biomarker • IO biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor • CXCL1 • NOS2

Revolutionizing prognosis: Introducing cell death index (CDI) as a powerful prognostic tool for CSCC patients. (PubMed, Environ Toxicol) - "This investigation constructed a novel effective prognostic indicator of CDI in patients with CSCC and identified potential genes associated with cell death that could be targeted for prognosis and treatment of CSCC."

Journal • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Identification of Hepatocellular Carcinoma Subtypes Based on Global Gene Expression Profiling to Predict the Prognosis and Potential Therapeutic Drugs. (PubMed, Biomedicines) - "Subtype S1 appeared to be more sensitive to BMS-754807, JQ1, and Axitinib, while subtype S2 was more sensitive to SB505124, Pevonedistat, and Tamoxifen. HCC patients can be classified into two subtypes based on their gene expression profiles, which exhibit distinctions in terms of signaling pathways, the immune microenvironment, and drug sensitivity."

IO biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • COL11A1 • COL1A1

Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study. (PubMed, Mol Med) - "The CDI-based model, which was established using 14 PCD-related genes, accurately predicted the tumor microenvironment, immunotherapy response, and drug sensitivity of patients with SOC. Thus this model may help improve the diagnostic and therapeutic efficacy of PPPM."

Biomarker • IO biomarker • Journal • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

An integrated machine learning framework for developing and validating a prognostic risk model of gastric cancer based on endoplasmic reticulum stress-associated genes. (PubMed, Biochem Biophys Rep) - "Moreover, five specific targeted therapy drugs, namely BMS-754807, Dasatinib, JQ1, AZD8055 and SB505124, produced better results in the treatment of the high-risk group of patients. A new molecular prognostic model associated with ERS was established and validated for GC and showed relatively good discriminative and predictive ability. This model greatly expands the collection of weapons in the armoury of prognostic analysis in GC."

IO biomarker • Journal • Machine learning • Gastric Cancer • Oncology • Solid Tumor

Construction of a novel lipid drop-mitochondria-associated genetic profile for predicting the survival and prognosis of lung adenocarcinoma. (PubMed, Discov Oncol) - "Our results suggest that the LD-M risk score is an effective prognostic indicator for individualized treatment of LUAD."

IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CAV2 • CYP24A1

Ferroptosis-related prognostic model of mantle cell lymphoma. (PubMed, Open Med (Wars)) - "Finally, according to our model and computational drug sensitivity analysis, four small molecule compounds, BMS-754807, SB216763, Doramapimod, and Trametinib, were identified as potential therapeutic agents for patients with MCL. This study provides a prognostic model with ferroptosis-related gene signature for MCL. The results show that the model helps predict prognosis in MCL."

Journal • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ANXA1 • CCND1 • CD20 • IL1B • MS4A1 • YBX1

Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma. (PubMed, Cancers (Basel)) - "BMS-754807 with nab-paclitaxel produced substantially greater antitumor effects by increasing in vivo apoptosis, leading to increased mice survival compared to those of BMS-754807 or nab-paclitaxel monotherapy. Our outcomes support the use of BMS-754807, alone and in combination with nab-paclitaxel, as an efficient and innovative treatment choice for EAC."

Journal • Esophageal Adenocarcinoma • Esophageal Cancer • Gastrointestinal Cancer • Genetic Disorders • Obesity • Oncology • Solid Tumor • IR

Inhibition of Insulin-like Growth Factor 1 Receptor/Insulin Receptor Signaling by Small-Molecule Inhibitor BMS-754807 Leads to Improved Survival in Experimental Esophageal Adenocarcinoma (Multidisciplinary Digital Publishing Institute) - "Using multiple EAC cell lines, BMS-754807 and nab-paclitaxel were evaluated as mono and combination therapies for in vitro effects on cell proliferation, cell death, and cell movement. We then analyzed the in vivo anticancer potency with survival improvement with BMS-754807 and nab-paclitaxel mono and combination therapies. BMS-754807 monotherapy suppressed in vitro cell proliferation and wound healing while increasing apoptosis. BMS-754807, when combined with nab-paclitaxel, enhanced those effects on the inhibition of cell proliferation, increment in cell apoptosis, and inhibition of wound healing. BMS-754807 with nab-paclitaxel produced substantially greater antitumor effects by increasing in vivo apoptosis, leading to increased mice survival compared to those of BMS-754807 or nab-paclitaxel monotherapy."

Preclinical • Esophageal Adenocarcinoma • Oncology

Dissecting gastric cancer heterogeneity and exploring therapeutic strategies using bulk and single-cell transcriptomic analysis and experimental validation of tumor microenvironment and metabolic interplay. (PubMed, Front Pharmacol) - "Despite resistance to immunotherapy, the high-risk group showed sensitivity to molecular targeted agents directed at IGF-1R (BMS-754807) and the PI3K-mTOR pathways (AZD8186, AZD8055). This study unveils the intricate interplay between TME and metabolic pathways in gastric cancer, offering potential for enhanced diagnosis, patient stratification, and personalized treatment. Understanding molecular features in each subtype enriches our comprehension of gastric cancer heterogeneity and potential therapeutic targets."

Biomarker • Heterogeneity • IO biomarker • Journal • Tumor microenvironment • Gastric Cancer • Gastrointestinal Cancer • Microsatellite Instability • Oncology • Solid Tumor • CD36 • KYNU • MSI • SCARB1

Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer. (PubMed, Cells) - "Thus, we tested whether inhibition of insulin receptor/insulin-like growth factor 1 receptor with the drug BMS-754807 and/or lysosomal disruption with hydroxychloroquine (HCQ) could sensitize TNBC cells to the chemotherapy drug carboplatin. Additionally, we demonstrate the lack of overt in vivo toxicity with our combination regimens and, therefore, propose that metabolic targeting of TNBC may be a safe and effective strategy to increase sensitivity to chemotherapy. Thus, we conclude that the use of exogenous metabolic modulators, such as BMS-754807 or HCQ, in combination with chemotherapy warrants additional study as a strategy to improve therapeutic responses in women with TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Transplantation • Triple Negative Breast Cancer • IR

Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation. (PubMed, Discov Oncol) - "IL4I1 may play a role as promoter of cancer and prognostic indicator in patients. High expression of IL4I1 is associated with the state of tumor immunosuppression and may contribute to tumor-associated macrophage invasion. Therefore, IL4I1 may be a new therapeutic target for the treatment and prognosis of patients with cancer."

Journal • Pan tumor • Oncology • IL4 • IL4I1

Predicting colorectal cancer prognosis based on long noncoding RNAs of disulfidptosis genes. (PubMed, World J Clin Oncol) - "Our findings emphasizes the role of disulfidptosis in regulating tumor development, therapeutic response, and patient survival in CRC patients. For the clinical treatment of CRC, these important LncRNAs could serve as viable therapeutic targets."

IO biomarker • Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • IL17A

A ten long noncoding RNA-based prognostic risk model construction and mechanism study in the basal-like immune-suppressed subtype of triple-negative breast cancer. (PubMed, Transl Cancer Res) - "In addition, drug sensitivity analysis identified 3 compounds, including BMS-754807, cytochalasin b, and linifanib, that could have a potential therapeutic effect on patients with the BLIS subtype. The risk prognosis model showed good prognostic value for the BLIS subtype patients, and the ten lncRNAs may be potential therapeutic targets."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AR • DIO3OS • FZD10 • SPARCL1

Applying a Gene Reversal Rate Computational Methodology to Identify Drugs for a Rare Cancer: Inflammatory Breast Cancer. (PubMed, Cancer Inform) - "AZD-7545, BMS-754807, and nimesulide target known IBC relevant genes: PDK, Met, and COX, respectively. AG-14361, butalbital, and clobenpropit are known to be functionally relevant in DNA damage, cell cycle, and apoptosis, respectively. These findings support the use of the GRR approach to identify drug candidates and potential combination therapies that could be used to treat rare diseases such as IBC."

Journal • Breast Cancer • Oncology • Rare Diseases • Solid Tumor

HIGH-THROUGHPUT AND HIGH-CONTENT DRUG SCREENING ON A LARGE-SCALE PATIENT-DERIVED HIGH-RISK COLORECTAL ADENOMA ORGANOID PLATFORM (UEGW 2023) - "Four drugs including metformin, BMS754807, Panobinostat, and AT9283 were screened out as potential hits with generally consistent inhibitory efficacy on HRCA-PDOs. This study established a promising HRCA-PDO biobank and conducted the first high-throughput and high-content HRCA drug screening in order to shed light on prevention of colorectal cancer."

Clinical • Colorectal Cancer • Gastrointestinal Cancer • MYC • WNT3